Manufacturing and Regulatory Barriers to Generic Drug Competition: A Structural Model Approach
Published Online:26 Apr 2022https://doi.org/10.1287/mnsc.2022.4423
- Cited by
- American Economic Journal: Microeconomics, Vol. 17, No. 4
- 13 December 2023 | Management Science, Vol. 70, No. 10
- IEEE Transactions on Engineering Management, Vol. 71
- 1 January 2023 | SSRN Electronic Journal, Vol. 26
- SSRN Electronic Journal, Vol. 24
Volume 69, Issue 3
March 2023
Pages 1323-1934, iii-iv
Article Information
Supplemental Material
Metrics
Information
- Received:March 21, 2018
- Accepted:March 24, 2022
- Published Online:April 26, 2022
Copyright © 2022, INFORMS
Cite as
Yixin (Iris) Wang, Jun Li, Ravi Anupindi (2022) Manufacturing and Regulatory Barriers to Generic Drug Competition: A Structural Model Approach. Management Science 69(3):1449-1467.
https://doi.org/10.1287/mnsc.2022.4423
Keywords
The authors thank George Ball (Indiana University), David Canter (University of Michigan), Erin Fox (University of Utah), Sangeeta Goel (University of Michigan Health System), Matthew Rosenberg (FDA), Henry Wang (University of Michigan), and Prashant Yadav (INSEAD and Center for Global Development) for sharing valuable institutional knowledge about the generic pharmaceutical industry and its regulatory environment. The usual disclaimer applies.
